ArticleAnnals of the rheumatic diseases2022
Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index.
Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?Rheumatology international · 2026Review
- Body mass index and achievement of minimal disease activity in psoriatic arthritis across different classes of advanced therapy.Rheumatology (Oxford, England) · 2026Observational
- Article
- The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.EULAR rheumatology open · 2026Article
- Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study.Scientific reports · 2026Observational
- Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.Frontiers in immunology · 2026Review
- Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.Arthritis research & therapy · 2025Article
- A Lymphatic Perspective on Obesity and Inflammatory Arthritis: New Disease-Modifying Potential in Rheumatology.Journal of clinical medicine · 2025Article
- Navigating Psoriatic Arthritis: Treatment Pathways and Patient-Specific Strategies for Improved Outcomes.Drugs · 2025Review
- Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.Arthritis research & therapy · 2024Observational
- Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort.Frontiers in medicine · 2024Article
- Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis.Yonsei medical journal · 2023Article
- Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience.Journal of clinical medicine · 2023Article
- Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.Frontiers in immunology · 2023Review
- Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?Mediterranean journal of rheumatology · 2022Review
- Article
- Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.Rheumatology and therapy · 2022Review
- The cardiometabolic conditions of psoriatic disease.Frontiers in immunology · 2022Review
- Metabolic Syndrome and Its Components in Psoriatic Arthritis.Open access rheumatology : research and reviews · 2022Review
- Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning.Frontiers in medicine · 2022Article
Corrections and comments
- Comment on
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.